Asker Healthcare Group AB (ASKER) AI Stock Analysis

• Market Cap: kr32.54B
• Dividend Yield: N/A
• Average Volume (3M): 1.96M
• Price to Earnings (P/E): ―
• Beta (1Y): 0.79
• Revenue Growth: N/A
• EPS Growth: N/A
• Country: SE
• Employees: 4,238
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Care Facilities
• EPS (TTM): 0.62
• Shares Outstanding: 383,036,500
• 10 Day Avg. Volume: 378,678
• 30 Day Avg. Volume: 1,960,693
• PEG Ratio: 1.15
• Price to Book (P/B): 9.24
• Price to Sales (P/S): 2.13
• P/FCF Ratio: 36.47
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 0

• Rating: 64 Neutral
• Price Target: kr90.00 ▲(7.40% Upside)

Asker Healthcare Group AB's overall stock score is driven primarily by its strong financial performance, characterized by robust revenue growth and improving operational margins. However, the technical analysis indicates bearish momentum, and the lack of valuation data adds uncertainty. The absence of earnings call insights and corporate events further limits the assessment.

Asker Healthcare Group AB Business Overview & Revenue Model

Company Description

Asker Healthcare Group AB (ASKER) is a prominent player in the healthcare sector, focusing primarily on the development and distribution of innovative pharmaceutical products and medical devices. The company operates in various therapeutic areas, including pain management, infectious diseases, and chronic illness care, offering a diverse portfolio that caters to both healthcare providers and patients. With a commitment to improving health outcomes, ASKER leverages advanced research and development capabilities to create effective solutions that address unmet medical needs.

How the Company Makes Money

ASKER generates revenue through multiple streams, primarily by selling its pharmaceutical products and medical devices to healthcare providers, hospitals, and pharmacies. The company employs a direct sales model as well as partnerships with distributors to expand its market reach. Additionally, ASKER may engage in licensing agreements for its proprietary technologies, allowing other companies to utilize its innovations in exchange for royalties or upfront fees. Strategic partnerships with research institutions and other healthcare entities also contribute to funding and collaborative development projects, enhancing ASKER's product pipeline and market presence. Overall, the combination of direct sales, licensing, and partnerships forms the backbone of ASKER's revenue model.

Asker Healthcare Group AB Financial Statement Overview

Summary

Asker Healthcare Group AB demonstrates strong financial performance with significant revenue growth and improved operational margins. The company's cash flow is robust, supporting growth and operational needs. Moderate leverage and a stable equity base provide a solid financial foundation.

Income Statement

Asker Healthcare Group AB has demonstrated strong revenue growth, with a 11.7% increase from 2023 to 2024. The gross profit margin is solid at 39.1%, and there is significant improvement in the EBIT margin to 6.4% from 4.3% in the previous year, indicating enhanced operational efficiency. The EBITDA margin also improved to 9.8%. However, the net profit margin is relatively low at 2.4%, reflecting potential non-operational costs or tax impacts.

Balance Sheet

The company's debt-to-equity ratio is 1.72, indicating moderate leverage but a slight increase in debt levels. The equity ratio of 26.4% suggests a balanced asset structure, though with room for improvement. Return on equity stands at 10.4%, which is reasonable but could be enhanced for better shareholder returns.

Cash Flow

Operating cash flow to net income ratio is robust at 3.41, suggesting strong cash generation relative to profits. There is a slight decline in free cash flow from 2023 to 2024, but the free cash flow to net income ratio remains favorable at 2.44. The overall cash flow generation is positive, supporting growth and operational needs effectively.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	7.98B	15.03B	13.45B	11.72B	9.35B
Gross Profit	3.26B	5.88B	4.52B	3.78B	2.61B
EBITDA	654.00M	1.47B	1.12B	1.12B	670.00M
Net Income	220.00M	360.00M	203.00M	430.00M	467.00M
Balance Sheet
Total Assets	15.21B	13.12B	11.33B	10.23B	7.36B
Cash, Cash Equivalents and Short-Term Investments	1.32B	490.00M	391.00M	211.00M	494.00M
Total Debt	5.11B	5.96B	4.97B	4.74B	3.93B
Total Liabilities	8.78B	9.62B	8.29B	7.44B	5.54B
Stockholders Equity	6.39B	3.47B	3.02B	2.76B	1.79B
Cash Flow
Free Cash Flow	42.00M	879.00M	901.00M	853.00M	258.00M
Operating Cash Flow	320.00M	1.23B	1.05B	976.00M	382.00M
Investing Cash Flow	-1.27B	-1.46B	-783.00M	-1.86B	-843.00M
Financing Cash Flow	1.81B	305.00M	-83.00M	572.00M	619.00M

Asker Healthcare Group AB Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
VITR	―	kr20.15B	45.23	3.34%	0.73%	-1.29%	―
ASKER	―	kr32.54B	―	―	―	―	―
ALIF.B	―	$22.32B	65.92	7.24%	0.37%	5.14%	236.75%
MCOV.B	―	kr39.18B	81.00	―	0.56%	15.92%	82.51%
ARJO.B	―	$8.50B	19.41	5.42%	3.09%	-0.05%	-13.44%
EKTA.B	―	kr18.66B	68.11	2.76%	4.91%	-1.54%	-75.84%
Sector *	―	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

Asker Healthcare Group AB Corporate Events

Asker Healthcare Group Announces Q3 2025 Webcast Presentation

Asker Healthcare Group has announced a webcast presentation for its Q3 2025 interim report, scheduled for November 6, 2025. The event will feature presentations by CEO Johan Falk and CFO Thomas Moss, followed by a Q&A session, offering stakeholders insights into the company’s recent performance and strategic direction.

The most recent analyst rating on (SE:ASKER) stock is a Hold with a SEK90.00 price target. To see the full list of analyst forecasts on Asker Healthcare Group AB stock, see the SE:ASKER Stock Forecast page.

Asker Healthcare Group Acquires Novus Med to Enhance UK Surgical Offerings

Asker Healthcare Group has acquired Novus Med Holdings Limited, a UK-based distributor specializing in endoscopic surgery technologies and patient positioning systems. This acquisition enhances Asker’s presence in the UK surgical field, adding innovative technologies in minimally invasive surgery and strengthening its partnership with hospitals. The acquisition is expected to positively impact the group’s EBITA margin, further solidifying its industry position.

The most recent analyst rating on (SE:ASKER) stock is a Hold with a SEK144.00 price target. To see the full list of analyst forecasts on Asker Healthcare Group AB stock, see the SE:ASKER Stock Forecast page.

Asker Healthcare Group Announces Changes in Nomination Committee

Asker Healthcare Group announced a change in its Nomination Committee ahead of the 2026 Annual General Meeting, with Richard Torgerson from Nordea Funds replacing Carina Silberg from Alecta. This change reflects shifts in share ownership and may influence the strategic direction of the company as it prepares for its upcoming AGM. Stakeholders are invited to submit proposals to the Nomination Committee by January 23, 2026, ahead of the AGM scheduled for May 7, 2026.

The most recent analyst rating on (SE:ASKER) stock is a Hold with a SEK144.00 price target. To see the full list of analyst forecasts on Asker Healthcare Group AB stock, see the SE:ASKER Stock Forecast page.

Asker Healthcare Group Announces Nomination Committee for 2026 AGM

Asker Healthcare Group AB has announced the formation of its Nomination Committee for the Annual General Meeting in 2026, based on the ownership structure as of August 29, 2025. The committee includes representatives from major shareholders and will oversee proposals for the meeting scheduled for May 7, 2026. This development reflects the company’s commitment to structured governance and stakeholder engagement, potentially impacting its strategic direction and shareholder relations.

The most recent analyst rating on (SE:ASKER) stock is a Hold with a SEK144.00 price target. To see the full list of analyst forecasts on Asker Healthcare Group AB stock, see the SE:ASKER Stock Forecast page.

Asker Healthcare Group Acquires Oudshoorn to Expand Medical Device Offerings

Asker Healthcare Group has announced the acquisition of Oudshoorn Chirurgische Techniek B.V., a leading distributor of medical devices in orthopaedics and trauma in the Netherlands. This strategic acquisition is expected to enhance Asker’s offerings to hospitals and private clinics by adding new product categories and expertise for operating rooms, thereby strengthening its position in the healthcare sector. The acquisition is anticipated to be completed in early September 2025 and is expected to positively impact the group’s EBITA margin.

The most recent analyst rating on (SE:ASKER) stock is a Hold with a SEK144.00 price target. To see the full list of analyst forecasts on Asker Healthcare Group AB stock, see the SE:ASKER Stock Forecast page.

Asker Healthcare Group Implements Long-Term Investment Share Program

Asker Healthcare Group AB held an Extraordinary General Meeting where they adopted a long-term performance-based investment share program for their management team and key employees. The meeting also authorized the issuance and management of Class C shares to support this program, reflecting a strategic move to enhance employee engagement and align interests with company performance.

The most recent analyst rating on (SE:ASKER) stock is a Hold with a SEK144.00 price target. To see the full list of analyst forecasts on Asker Healthcare Group AB stock, see the SE:ASKER Stock Forecast page.

Asker Healthcare Group Expands UK Presence with HNC Acquisition

Asker Healthcare Group has acquired Health Net Connections Limited (HNC), a UK-based provider of healthcare software specializing in digital diagnostic imaging and ultrasound reporting. This acquisition strengthens Asker’s position in the region and expands its offerings in the UK market, with an expected positive contribution to the group’s EBITA margin.

The most recent analyst rating on (SE:ASKER) stock is a Buy with a SEK100.00 price target. To see the full list of analyst forecasts on Asker Healthcare Group AB stock, see the SE:ASKER Stock Forecast page.

Asker Healthcare Group Expands into French Market with Finmed Acquisition

Asker Healthcare Group has announced its acquisition of 80% of Finmed SAS, a leading provider of medical devices and solutions in France. This strategic move marks Asker’s first acquisition in France, aiming to strengthen its presence in the large French healthcare market. The acquisition, which is pending regulatory approval, is expected to close in the fourth quarter of 2025 and positively impact the group’s EBITA margin.

The most recent analyst rating on (SE:ASKER) stock is a Buy with a SEK100.00 price target. To see the full list of analyst forecasts on Asker Healthcare Group AB stock, see the SE:ASKER Stock Forecast page.